Clinique La Prairie targets epigenetic wellness with Epinome supplement launch

Global – Clinique La Prairie has launched Epinome, an ultra-targeted supplement designed to support cellular health and longevity through epigenetic regulation. Developed over three years in collaboration with epigenetic testing firm Genknowme, the product reflects the clinic’s commitment to cutting-edge nutraceutical science. Epinome works at a molecular level to restore healthy methylation patterns – a process vital to regulating gene expression and cellular repair.

The formula combines seven plant-based compounds, including sulforaphane and cucurbitacin B, with Clinique La Prairie’s proprietary Holistic Complex to combat inflammation, oxidative stress and cellular decline. Backed by rigorous epigenetic testing, it addresses one of the 12 recognised mechanisms of ageing.

Positioned within the brand’s Holistic Health range, Epinome marks a bold expansion into at-home longevity solutions, with a 30-day supply priced at £390 ($519, €460). Launching in June 2025, it will be stocked at premium retailers including Harrods and Mandarin Oriental.

Our Breakthrough Biohacks report spotlights the pathways and biohacks maximising longevity and effectively treating and preventing age-related conditions.